Current opinion in gastroenterology
-
Curr. Opin. Gastroenterol. · Jul 2015
ReviewBiosimilars in inflammatory bowel disease: ready for prime time?
The goal is to review the most recent literature about biosimilars in inflammatory bowel disease (IBD), with emphasis on controversial regulatory issues. ⋯ Biosimilars in IBD are here to stay. New data are awaited to settle the controversy of extrapolation, but only the complex behavior of markets will show whether biosimilars fuel competition and extend access to biologics with significant cuts in drug costs.